Effect of indoleamine 2,3-dioxygenase on immune escape mechanism in malignant glioma

吲哚胺2,3-双加氧酶对恶性胶质瘤免疫逃逸机制的影响

• 批准号: 20591709
• 负责人: SATOU Eiji
• 金额: $ 2.91万
• 依托单位: University of Yamanashi
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2008
• 资助国家: 日本
• 起止时间: 2008 至 2010
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20591709/
• 关键词: インドールアミン2,3-ジオキシゲナーゼ; グリオーマ; 免疫回避機構; IDO; malignant glioma; prognosis; glioma; immunohistochemistry; 悪性グリオーマ; western blot法; RT-PCR法; 免疫組織染色法; 免疫抑制作用

Indoleamine 2,3-dioxygenase (IDO) is a tryptophan catabolic enzyme participating in immune tolerance and tumor immune escape process. Recently, IDO expression has been found to correlate with prognosis of malignant tumor, but the involvement of IDO in glioma progression remains unknown. The present study investigated the relationship between IDO expression and histological malignance in glioma. IDO expression rate was compared in each histological grade, and survival analysis in correlation with IDO expression was performed. IDO was expressed in 71 of 74 gliomas with varying intensities. IDO was strongly expressed in malignant gliomas, and weekly in low grade gliomas. Survival analysis by the Kaplan-Meier methods revealed that patients with higher IDO expression tended to have poorer clinical outcome compared with lower IDO expression. The present study suggests that IDO expression in glioma cells promotes tumor malignancy and may affect clinical outcome.

吲哚胺2,3-双加氧酶（IDO）是一种色氨酸分解代谢酶，参与免疫耐受和肿瘤免疫逃逸过程。最近发现IDO表达与恶性肿瘤的预后相关，但IDO在神经胶质瘤进展中的作用仍不清楚。本研究调查了神经胶质瘤中IDO表达与组织学恶性之间的关系。比较各组织学分级中的IDO表达率，并进行与IDO表达相关的生存分析。 IDO 在 74 个神经胶质瘤中的 71 个中以不同强度表达。 IDO 在恶性神经胶质瘤中强烈表达，在低级别神经胶质瘤中每周表达。 Kaplan-Meier 方法的生存分析显示，与 IDO 表达较低的患者相比，IDO 表达较高的患者往往临床结果较差。目前的研究表明，神经胶质瘤细胞中的 IDO 表达会促进肿瘤恶性，并可能影响临床结果。